ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $256,858,415 | -15.2% | 9,464,201 | -3.9% | 1.04% | -16.0% |
Q2 2023 | $302,817,650 | -25.0% | 9,850,932 | -12.1% | 1.24% | -34.6% |
Q1 2023 | $403,689,091 | +2.1% | 11,204,249 | +11.9% | 1.90% | -4.3% |
Q4 2022 | $395,536,355 | -9.5% | 10,008,511 | -8.0% | 1.98% | -1.9% |
Q3 2022 | $437,222,000 | -15.9% | 10,881,594 | -12.0% | 2.02% | -15.1% |
Q2 2022 | $520,064,000 | +24.0% | 12,370,694 | +14.9% | 2.38% | +40.3% |
Q1 2022 | $419,384,000 | +2.0% | 10,764,472 | +4.4% | 1.70% | +43.2% |
Q4 2021 | $411,068,000 | +174.7% | 10,315,378 | +149.1% | 1.18% | +188.8% |
Q3 2021 | $149,638,000 | +12.7% | 4,140,508 | +27.8% | 0.41% | +2.0% |
Q2 2021 | $132,752,000 | +47.6% | 3,238,654 | +57.1% | 0.40% | +50.0% |
Q1 2021 | $89,934,000 | -21.4% | 2,061,753 | -9.8% | 0.27% | -14.9% |
Q4 2020 | $114,464,000 | +39.7% | 2,287,000 | +17.4% | 0.32% | +6.4% |
Q3 2020 | $81,955,000 | -32.9% | 1,948,064 | -22.5% | 0.30% | -43.9% |
Q2 2020 | $122,103,000 | – | 2,514,985 | – | 0.53% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |